Q2 2026 saw revenue rise 17.2% year-over-year to $707.3M, with net income up 34.5% and EBITDA margin steady at 21.7%. Full-year guidance was raised, reflecting strong new business awards and backlog growth, while share repurchases and cash flow remained robust.Original document: Medpace Holdings, I…
Q2 2026 saw revenue rise 17.2% year-over-year to $707.3M, with net income up 34.5% and EBITDA margin steady at 21.7%. Full-year guidance was raised, reflecting strong new business awards and backlog growth, while share repurchases and cash flow remained robust.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.